SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new development or finding in product specification without further noticed.
Chemical Name: 2-((8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl ethyl carbonate
Shipping Temperature: Ambient
HSN Code: 38229010
Country of Origin: India
Smiles: C[C@@]1([C@@]2(O)C(COC(OCC)=O)=O)[C@](CC2)([H])[C@@](CCC3=CC4=O)([H])[C@]([C@]3(C=C4)C)([H])[C@@H](O)C1
Loteprednol Impurity 2 is chemically 2-((8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl ethyl carbonate. Loteprednol Impurity 2 is supplied with detailed characterization data compliant with regulatory guideline. Loteprednol Impurity 2 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Loteprednol.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Potential Use of Cyclodextrin Complexes for Enhanced Stability, Anti-inflammatory Efficacy, and Ocular Bioavailability of Loteprednol Etabonate
By Soliman, Osama Abd El-Aazeem; Mohamed, Elham Abdel Monem; El-Dahan, Marwa Salah; Khatera, Nabil Abdullah Ali
From AAPS PharmSciTech (2017), 18(4), 1228-1241
Determination of edetate disodium dihydrate in loteprednol and tobramycin ophthalmic suspension by RP-HPLC
By Xue, Qi; Yang, Longhua
From Zhongguo Yaoye (2012), 21(1), 24-25
An HPLC method to evaluate purity of a steroidal drug, loteprednol etabonate
By Yasueda, Shin-ichi; Higashiyama, Masayo; Shirasaki, Yoshihisa; Inada, Katsuhiro; Ohtori, Akira
From Journal of Pharmaceutical and Biomedical Analysis (2004), 36(2), 309-316